SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)
$NTLA
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/21/2025 | $21.00 | Peer Perform → Outperform | Wolfe Research |
| 3/5/2025 | $30.00 | Buy | H.C. Wainwright |
| 2/28/2025 | $45.00 → $13.00 | Overweight → Neutral | Analyst |
| 2/28/2025 | $9.00 | Neutral → Sell | Goldman |
| 1/27/2025 | $56.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/23/2024 | $136.00 → $32.00 | Buy → Neutral | Goldman |
| 2/15/2024 | Peer Perform | Wolfe Research | |
| 4/13/2023 | $66.00 | Buy | Canaccord Genuity |
Wolfe Research upgraded Intellia Therapeutics from Peer Perform to Outperform and set a new price target of $21.00
H.C. Wainwright initiated coverage of Intellia Therapeutics with a rating of Buy and set a new price target of $30.00
Analyst downgraded Intellia Therapeutics from Overweight to Neutral and set a new price target of $13.00 from $45.00 previously
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
SCHEDULE 13G - Intellia Therapeutics, Inc. (0001652130) (Subject)
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR
Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do
- Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of A
On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002 in patients with HAE at EAACI Congress in June 2025Expect to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available throug
Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027Enrollment in the pivotal Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis (ATTR) with cardiomyopathy continues to track ahead of projections; more than 550 total patients expected to be enrolled by year endActively screening for the Phase 3 MAGNITUDE-2 trial for nex-z in hereditary ATTR amyloidosis with polyneuropathy; on track to dose first patient in 1Q25En
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were previously progressing on patisiranContinue to observe generally favorable safety and tolerability data in the full Phase 1 cohort with no new drug-related adverse events within the follow-up periodEnrollment continues to progress well in MAGNITUDE-2, which is designed to measure clinical outcomes (including mNIS+7) and evaluate how a single dose of nex-z can lead to reduction in serum TTR, to potentially support a BLA submission by 2028 CAMBRIDG
On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002 in patients with HAE at EAACI Congress in June 2025Expect to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an inducement grant to eight new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units ("RSUs") for 69,600 shares of Intellia's common stock, with one-third of such RSUs vesting on May 1, 2026, 2027 and 2028. All equity vesting is subject to each employee's continued service as an employee of, or other service provider to, Intellia through
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)